Troxevasin gel 2% (Troxerutine) 40 g # 423-02 PB(3,5)
Troxevasin (Troxerutine) caps 300 mg x 50 # 423-03 PB(3,5)

COMPOSITION:
Troxerutine gel 2% 40 g
Troxerutine 300 mg

THERAPEUTIC GROUP: Cardiovascular System

THERAPEUTIC SUBGROUP: Antivaricosis & Antihaemorrhoidal Preparations

DESCRIPTION: Troxevasin treats capillaries by increasing their endurance and lowering the permeability of the venous blood vessel walls.

APPLICATION: Perorally!(capsules) External use for gel.

HOW SUPPLIED: capsules 300 mg gel 2% 40 g

ACTION: The drug exerts anti-varicose action by enhancing capillary stability and normalizing their permeability. It has also a certain anti-inflammatory effect.

As a result of these pharmacologic effects troxevasin relieves oedema, pain and trophic disturbances and makes possible the effective treatment of chronic venous failure and its complications.

INDICATIONS

Venous insufficiency of the lower limbs and haemorrhoids.
For the treatment of:

• pre-varicous and varicous syndrome,
• varicous ulcers,
• superficial thrombophlebitis, phlebitis, post-phlebitis conditions,
• chronic venous insufficiency,
• haemorrhoids,
• retinopathy,
• muscular cramps,
• pains of traumatic origin - following contusions, distorsions, luxations and etc.,
• edema and pain in trauma and varicous veins,
• varicous dermatitis.

As an adjuvant in the treatment of scleropathy and venectomy.

CONTRAINDICATIONS: History of sensitivity to rutosides.

ADVERSE REACTIONS: Very rarely allergic skin reactions, gastric discomfort, reddening of the face and headache may occur. Withdrawal of treatment is not necessary.

DRUG INTERACTIONS: Interactions with other medications have not been reported. Troxevasin does not affect anticoagulants of the coumarin type. The drug can be combined with other venotonic preparations or with local medicinal forms of that group.

SPECIAL PRECAUTIONS FOR USE: Troxevasin shuld be used carefully on patients with liver and bile deseases. The drug has to be taken together with meals because it irritates the ventricular system.

PREGNANCY AND BREAST-FEEDING: Adverse reactions on the reproductive function or data for embryotoxic or teratogenic action of the drug have not been established. However, with regard to foetus safety troxevasin should not be prescribed during the pregnancy. During the rest of the period the drug may be administered only after the potential benefits have been weighed against the possible hazards.

EFFECTS ON ABILITY TO DRIVE AND USE MACHINES: Adverse effects on active attention, reflexes and driving ability have not been reported.

DOSAGE: In varicose diseases 1 capsule 2 times daily in the morning and in the evening; for maintenance therapy 1 capsule daily for a period of 3-4 weeks or longer.

The capsules should be taken during meals with some liquid.

OVERDOSAGE: No specific clinical symptoms of overdosage have been reported. Feeling of heaviness and discomfort in the stomach, nausea and vomiting may occur. In case of overdosage treatment should be withdrawn. Measures include elimination of the drug from the system and symptomatic therapy.

STORAGE: In a dry place protected from light at 15-25ºC.

EXPIRY TERM: 5 years